TABLE 1.
Full bivariate analysis
| Characteristicd | Patients with an eCrCL of: |
P valuee | |
|---|---|---|---|
| <30 ml/min (n = 40) | ≥30 ml/min (n = 307) | ||
| Baseline demographics and treatment information | |||
| Age (median [IQR] [yrs]) | 80 (63.8–89) | 62 (54–74) | <0.001a |
| Female gender (no. [%]) | 23 (57.5) | 146 (47.6) | 0.237b |
| Body mass index of >30 kg/m2 (no. [%]) | 14 (35) | 149 (48.5) | 0.117b |
| Cirrhosis (no. [%]) | 2 (5) | 4 (1.3) | 0.114c |
| Diabetes mellitus (no. [%]) | 24 (60) | 95 (30.9) | <0.001b |
| Heart failure (no. [%]) | 18 (45) | 33 (10.7) | <0.001b |
| Hypertension (no. [%]) | 34 (85) | 176 (57.3) | <0.001b |
| Renal transplant (no. [%]) | 1 (2.5) | 3 (1) | 0.389c |
| Baseline SCr (median [IQR] [mg/dl]) | 1.2 (1–2.1) | 0.85 (0.7–1) | <0.001a |
| SCr on the day of remdesivir administration (median [IQR] [mg/dl]) | 2.8 (1.6–4.2) | 0.87 (0.7–1.1) | <0.001a |
| CrCl (ml/min) on the day of remdesivir administration by C-G (median [IQR]) | 20.3 (15.3–26.3) | 82.5 (57.8–108.6) | <0.001a |
| eGFR (ml/min/1.73 m2) on the day of remdesivir administration by MDRD (median [IQR]) | 21 (15.2–34.1) | 89.4 (63.8–111.7) | <0.001a |
| ALT > 5× ULN on the first day of remdesivir administration | 0.638c | ||
| Total no. | 40 | 304 | |
| No. (%) | 2 (5) | 10 (3.3) | |
| In AKI on the day of remdesivir administration (no. [%]) | 16 (40) | 8 (2.6) | <0.001b |
| Vasopressor or inotrope use during remdesivir (no. [%]) | 12 (30) | 39 (12.7) | 0.003b |
| Mechanical ventilation during remdesivir (no. [%]) | 11 (27.5) | 38 (12.4) | 0.01b |
| Concomitant nephrotoxic drug (no. [%]) | |||
| Vancomycin | 5 (12.5) | 52 (16.9) | 0.65c |
| Aminoglycoside | 1 (2.5) | 0 (0) | 0.115c |
| i.v. acyclovir | 1 (2.5) | 0 (0) | 0.115c |
| TMP-SMX | 0 (0) | 4 (1.3) | >0.999c |
| Amphotericin B | 0 (0) | 0 (0) | >0.999c |
| ACE/ARB | 8 (20) | 50 (16.3) | 0.554b |
| Loop/thiazide diuretics | 24 (60) | 106 (34.5) | 0.002b |
| Tacrolimus/cyclosporine | 1 (2.5) | 3 (1) | 0.389c |
| i.v. contrast | 3 (7.5) | 41 (13.4) | 0.447c |
| NSAIDS | 0 (0) | 7 (2.3) | >0.999c |
| Days of remdesivir treatment (median [IQR]) | 5 (4–5) | 5 (5–5) | 0.002a |
| Safety outcomes | |||
| AKI using EOT SCr | 0.283c | ||
| Total no. | 40 | 303 | |
| No. (%) | 2 (5) | 7 (2.3) | |
| AKI using peak SCr (no. [%]) | 2 (5) | 11 (3.6) | 0.652c |
| AKI 48 h posttreatment | 0.212c | ||
| Total no. | 21 | 173 | |
| No. (%) | 3 (14.3) | 12 (6.9) | |
| ALT > 5× ULN on last day of remdesivir | 0.145c | ||
| Total no. | 38 | 294 | |
| No. (%) | 0 (0) | 19 (6.5) | |
| Remdesivir discontinued early due to abnormal LFTs (no. [%]) | 0 (0) | 12 (3.9) | 0.374c |
| 30-day mortality | <0.001b | ||
| Total no. | 34 | 232 | |
| No. (%) | 19 (55.9) | 38 (16.4) | |
a
Mann-Whitney U test.
b
Chi-square test.
c
Fisher’s exact test.
d
C-G, Cockgrauft-Gault equation; MDRD, modification of diet in renal disease; TMP-SMX, trimethoprim-sulfamethoxazole; ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blocker; NSAIDS, nonsteroidal anti-inflammatory drugs; SCr, serum creatinine; LFTs, liver function tests.
e
Bolded values are P < 0.05.